Scholars Central

Conference abstractPublished 30 Aug 2022

U.S. Biosimilars Market - A Deep Dive

Authors: Aiswariya Chidambaram

Associate Director, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Ever since the approval of the first biosimilar drug in the U.S. in 2015, 31 biosimilars have been approved till date (as of September 2021). While 2019 witnessed a steep surge in the approval rates of biosimilars, the COVID-19 pandemic and the resulting lockdown did slow down the approval rates over the last one year (2020 âÂ?Â? 2021). Nevertheless, the U.S. biosimilars market is poised to witness a significant growth of 25% (CAGR) over the next seven years (2021 âÂ?Â? 2028) propelled by the patent expiry of key blockbuster drugs, increased cost-saving initiatives and conducive regulatory framework established by the U.S. government, strategic partnerships, and industry consolidation in addition to the rising incidence of chronic diseases and aging baby-boomer population. Both the biotech firms as well as regulatory authorities have emerged resilient and geared well to a post-pandemic world. This market research service analyses the revenue prospects of the U.S. biosimilars market (in terms of market size, growth rates, YOY revenue forecasts, etc.), patent cliff (biologic drugs due to lose patent protection), key therapeutic areas overview, competitive landscape, key strategic alliances, regulatory framework, pricing and reimbursement policies as well as impact mapping of patients, physicians and payers. Furthermore, strategic recommendations for the success of market participants have also been discussed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Cancer Diagnosis.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Cancer Diagnosis
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Aiswariya Chidambaram”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels